Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
glioblastoma multiforme multipeptide vaccine IMA950 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| glioblastoma multiforme multipeptide vaccine IMA950 | BIOLOGICAL | - |
| sargramostim | BIOLOGICAL | - |
| temozolomide | DRUG | - |
| laboratory biomarker analysis | OTHER | - |
| pharmacological study | OTHER | - |
| adjuvant therapy | PROCEDURE | - |
| radiation therapy | RADIATION | - |
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed glioblastoma multiforme (astrocytoma WHO grade IV disease) * Newly diagnosed disease * Resectable tumor (not including patients undergoing biopsy only or tumors involving the brain stem or cerebellum) * Meets 1 of the followi...
IMA950 is an investigational multipeptide vaccine developed by Immatics N.V. for glioblastoma multiforme, a type of brain and central nervous system tumor. It is designed to stimulate an immune response against tumor-associated peptides and has been studied in a Phase 1 clinical trial in newly diagnosed patients.
IMA950 is being developed for the treatment of newly diagnosed glioblastoma multiforme, a brain and central nervous system tumor. It is intended to be used in combination with standard therapies, specifically temozolomide and radiation therapy, as investigated in a Phase 1 clinical trial.
IMA950 is being developed by Immatics N.V., a biopharmaceutical company traded on the Nasdaq under the ticker symbol IMTX. Immatics focuses on the discovery and development of T cell receptor-based immunotherapies and vaccines for cancer.
IMA950 is in Phase 1 clinical development. It has completed one Phase 1 trial, and no active trials are currently listed. The vaccine remains investigational and has not been approved by the FDA or any regulatory agency for commercial use.
IMA950 has been evaluated in a completed Phase 1 clinical trial, NCT01222221, titled "Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme." The trial enrolled 45 patients in the United Kingdom and was an uncontrolled, non-randomized study.